Synthokind Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -0.35%
(FY 2023)
- Profit -24.44%
(FY 2023)
- Ebitda -4.70%
(FY 2023)
- Net Worth 32.56%
(FY 2023)
- Total Assets 2.61%
(FY 2023)
About Synthokind Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Veena Mittal and Amit Mittal serve as directors at the Company.
- CIN/LLPIN
U51909DL2014PTC264328
- Company No.
264328
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Synthokind Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veena Mittal  | Director | 12-Jan-2017 | Current |
| Amit Mittal | Additional Director | 26-Mar-2018 | Current |
Financial Performance of Synthokind Pharmaceuticals.
Synthokind Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.35% decrease. The company also saw a substantial fall in profitability, with a 24.44% decrease in profit. The company's net worth Soared by an impressive increase of 32.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synthokind Pharmaceuticals?
In 2023, Synthokind Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maa Bala Zinc And Alloys Industries Private LimitedActive 10 years 21 daysAmit Mittal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synthokind Pharmaceuticals?
Unlock and access historical data on people associated with Synthokind Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synthokind Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synthokind Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
